Learn about Sofosbuvir, a powerful antiviral medication used to treat Hepatitis C. Discover its mechanism of action and effectiveness in clearing the virus.

The COSMOS study was a phase 2a clinical trial that showed high cure rates of genotype 1 chronic hepatitis C (CHC) and a favorable side effect profile using a 12-week regimen of simeprevir + sofosbuvi...

Atea Pharmaceuticals (Nasdaq: AVIR) reported second quarter 2026 results and key viral hepatitis pipeline progress. The Phase 3 C-BEYOND trial of bemnifosbuvir/ruzasvir (BEM/RZR) for HCV met its primary and secondary non-inferiority endpoints versus sofosbuvir/velpatasvir, with sustained virologic response (SVR) of 93.9% vs. 94.8% in the mITT population (n=905). Non‑cirrhotic patients achieved a 93.5% SVR with 8 weeks of BEM/RZR vs. 94.6% with 12 weeks of SOF/VEL; cirrhotic patients had 95.4% SVR in both arms. BEM/RZR was generally safe and well tolerated with no drug‑related serious adverse events.Atea completed enrollment of its second Phase 3 trial, C-FORWARD, with over 880 patients across 17 countries and expects topline data in early Q1 2027, targeting an NDA submission in Q2 2027. A first‑in‑human Phase 1 trial of AT‑587 for chronic HEV started in July. At June 30, 2026, cash, cash equivalents and marketable securities were $219.5 million (vs. $301.8 million at December 31, 2025). Q2 2026 research and development expense was $28.2 million (down from $32.3 million), general and administrative expense was $6.9 million (down from $9.1 million), and net loss was $32.9 million, or $0.41 per share, compared to $37.2 million, or $0.44 per share, a year earlier.

Atea Pharmaceuticals’ hepatitis C prospect has

Atea Pharmaceuticals (Nasdaq: AVIR) reported positive topline Phase 3 C-BEYOND results in North America for its once-daily fixed-dose combination bemnifosbuvir/ruzasvir (BEM/RZR) in chronic hepatitis C virus (HCV). In the modified intent-to-treat population (n=905), BEM/RZR achieved a 93.9% sustained virologic response (SVR) at Week 24 versus 94.8% for standard-of-care sofosbuvir/velpatasvir (SOF/VEL; Epclusa), meeting the primary endpoint of statistical non-inferiority within a prespecified 5% margin.In patients without cirrhosis (n=721), 8 weeks of BEM/RZR achieved a 93.5% SVR versus 12 weeks of SOF/VEL with 94.6% SVR. In patients with cirrhosis (n=184), 12 weeks of each regimen yielded 95.4% SVR in both arms. Secondary endpoints, including per-protocol analysis, also met statistical non-inferiority. BEM/RZR was generally safe and well tolerated, with no drug-related serious adverse events or drug-related early discontinuations and safety comparable between arms. C-FORWARD, the companion Phase 3 trial outside North America with more than 880 patients enrolled, remains on track to report topline results in early 2027.

Transformative drugs often emerge from investment by public and private actors. Sofosbuvir changed hepatitis C care, but had public support through NIH. An estimated $60.9 million in public dollars su...

Atea Pharmaceuticals (Nasdaq: AVIR) completed patient enrollment in C-FORWARD, its Phase 3 trial outside North America evaluating the oral combination of bemnifosbuvir and ruzasvir (BEM/RZR) for chronic hepatitis C virus (HCV).C-FORWARD enrolled over 880 treatment‑naïve patients at ~120 sites in 17 countries, comparing BEM/RZR with sofosbuvir/velpatasvir. Topline results are expected around year-end 2026, with C-BEYOND topline data on track for mid‑2026. The program is described by Atea as the first global Phase 3 head‑to‑head DAA regimen comparison for HCV.

TO THE EDITOR—In their recent Major Article in The Journal of Infectious Diseases, Strunz and colleagues characterize peripheral NK-cell remodeling during acute symptomatic hepatitis C treated with a 6-week ledipasvir/sofosbuvir course [1, 2]. Using longitudinal flow cytometry in acute (n = 15), chronic (n = 12), and healthy controls (n = 20), together with CITE-seq in smaller acute and healthy subsets (n = 4 each), they define a transient, interferon-driven activation state during viremia. A key strength is the integrated view across transcriptomic activation modules and protein-defined NK phenotypes, with rapid normalization after DAA-mediated cure yet a measurable “imprint” persisting in select effector features [2].

The government of Malaysia has began to roll out treatment of people infected with the hepatitis C virus (HCV).  Treatment will be a combination of antivirals (sofosbuvir and daclatasvir) from generic...

Market size was valued at USD 4.2 Billion in 2024 and is poised to grow from USD 4.

A diferença entre o preço-teto autorizado pela Câmara de Regulação do Mercado de Medicamentos (CMED) e o valor de compra de remédios pelo SUS chega a ultrapassar 2.600% para o sofosbuvir, usado para hepatite C . No balcão das farmácias, sem levar em conta os tradicionais descontos, a maior diferença encontrada foi de 100% no clavulin, antibiótico usado para infecções bacterianas comuns ,mostra a quinta edição da pesquisa feita pelo Instituto de Defesa do Consumidor (Idec) que compara os preços-teto de medicamentos e os valores praticados em compras públicas e nas farmácias. Matéria exclusiva para assinantes. Para ter acesso completo, acesse o link da matéria e faça o seu cadastro.